Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
LEXICON PHARMACEUTICALS, INC. (LXRX)
|
Add to portfolio |
|
|
|
| Price: |
$3.89
| | Metrics |
| OS: |
244.9
|
M
| |
|
|
| Market cap: |
$953
|
M
| |
|
|
|
Net cash:
|
$152
|
M
| |
$0.62
|
per share
|
|
EV:
|
$800
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($100)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.1 | 0.3 | 24.0 | 322.1 | 63.2 | 91.7 | 79.3 | 130.0 |
| Revenue growth | -53.4% | -98.8% | -92.5% | 409.5% | -31.1% | 15.7% | -39.0% | 468.9% |
| Cost of goods sold | 0.0 | 0.0 | 1.9 | 3.2 | 2.5 | 1.9 | -207.1 | 0.0 |
| Gross profit | 0.1 | 0.3 | 22.1 | 318.8 | 60.7 | 89.8 | 286.4 | 130.0 |
| Gross margin | 100.0% | 100.0% | 92.0% | 99.0% | 96.1% | 97.9% | 361.3% | 100.0% |
| Research and development | 52.8 | 55.0 | 153.6 | 91.9 | 100.2 | 152.2 | 164.0 | 95.2 |
| General and administrative | 48.1 | 32.3 | 47.2 | 56.8 | 63.8 | 66.1 | 43.2 | 23.8 |
| EBIT | -100.8 | -87.1 | -46.2 | 170.1 | -103.3 | -130.6 | -127.2 | 11.0 |
| EBIT margin | -72489.2% | -29224.8% | -192.5% | 52.8% | -163.4% | -142.5% | -160.5% | 8.5% |
| Pre-tax income | -101.9 | -87.8 | -58.6 | 124.1 | -120.5 | -135.7 | -131.4 | -4.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | -6.0 | 0.0 | -12.7 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 9.3% | 0.0% | 0.0% |
| Net income | -101.9 | -87.8 | -58.6 | 130.1 | -120.5 | -123.0 | -131.4 | -4.7 |
| Net margin | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -134.1% | -165.8% | -3.6% |
| |
| Diluted EPS | ($0.62) | ($0.60) | ($0.53) | $1.11 | ($1.14) | ($1.17) | ($1.27) | ($0.05) |
| Shares outstanding (diluted) | 164.4 | 146.3 | 110.5 | 116.7 | 105.8 | 105.2 | 103.9 | 103.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|